TheraBiogen, Inc. Announces Launch of Direct Marketing Program With ECAP Capital for Thera Max(TM) Cold and Flu
Increasing ECAP's Total Commitment to Over $2 Million
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 10/20/11 -- TheraBiogen, Inc. (OTCBB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today that it has entered into a Direct Marketing Agreement (DMA) with ECAP Capital, LLC ("ECAP").
Kelly Hickel, CEO of TheraBiogen, commented, "With this marketing agreement, ECAP intends to invest more than $750,000 for a comprehensive national program." He continued, "We couldn't be more pleased with our ECAP partnership and its contribution to TheraBiogen."
Charles Brofman, Co-CEO of ECAP, added, "This direct response market initiative focusing on television and online should greatly increase the company's top-line, promote product awareness and drive consumer action at the retail store level." He went on to say, "We believe the direct response television program (DRTV) we are developing for Thera Max™ Cold and Flu could be as equally successful as the DRTV projects we fund for Packit®, () and Gourmè Mist™ () which are producing revenues in the millions of dollars. We anticipate launching this program in time for the fall cold and flu season."
Thera Max™ is available for purchase in over twelve thousand locations from Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts, Big Y Supermarkets and others. For more information on Thera Max™ visit our website or our Facebook page at facebook.com/theramaxnasalspray.
TheraBiogen, Inc. is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit .
ECAP is a privately held financial services company with multiple business lines. It provides varied financial services such as post settlement funding for law firms, purchase order financing, inventory financing, account receivable financing and financing for exports. In addition to Therabiogen, some of its representative clients are Packit, LLC (), Gourmè Mist™ () Sultra Corp. (), Discount Laptop Shop () and Progressive Products LLC ().
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.
TheraBiogen, Inc.
Kelly T. Hickel
Chairman and CEO
646-808-3095
Boutcher & Boutcher
Aimee Boutcher
973-239-2878
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.10.2011 - 06:30 Uhr
Sprache: Deutsch
News-ID 1048089
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 126 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TheraBiogen, Inc. Announces Launch of Direct Marketing Program With ECAP Capital for Thera Max(TM) Cold and Flu
"
steht unter der journalistisch-redaktionellen Verantwortung von
TheraBiogen, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
